Immuneering Corporation (IMRX)
NASDAQ: IMRX · Real-Time Price · USD
7.66
+0.15 (2.00%)
At close: Nov 28, 2025, 1:00 PM EST
7.55
-0.11 (-1.44%)
After-hours: Nov 28, 2025, 4:50 PM EST
Immuneering Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
66
Market Cap
494.61M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 316.95K | -1.76M | -84.76% |
| Dec 31, 2021 | 2.08M | -231.57K | -10.02% |
| Dec 31, 2020 | 2.31M | 391.83K | 20.41% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
IMRX News
- 4 days ago - Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference - GlobeNewsWire
- 16 days ago - Immuneering Corporation (IMRX) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 17 days ago - Immuneering Reports Third Quarter 2025 Financial Results and Provides Business and Clinical Updates - GlobeNewsWire
- 25 days ago - Immuneering to Report Third Quarter 2025 Financial Results and Provide New Clinical Case Studies, on Wednesday, November 12, 2025 - GlobeNewsWire
- 2 months ago - Immuneering Corporation - Special Call - Seeking Alpha
- 2 months ago - Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025 - GlobeNewsWire
- 2 months ago - Immuneering: Positive Pancreatic Cancer Data Atebimetinib Leads To Q4 2025 Catalyst - Seeking Alpha
- 2 months ago - Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi - GlobeNewsWire